What does this research mean for the field?

Placenta mesenchymal stromal cell-derived exosomes (HP-MSC-EVs) are safe and demonstrate early clinical efficacy in treating steroid-resistant acute graft-versus-host disease, providing a viable cell-free alternative to traditional whole-cell MSC therapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the safety and therapeutic efficacy of placental mesenchymal stromal cell-derived extracellular vesicles (HP-MSCs-EV) in patients experiencing steroid-resistant acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

September 2, 2026Stem Cell Research & TherapyOpen Access

Evaluating the safety of placenta mesenchymal stromal cells-derived exosomes (HP-MSCs-EV) in the treatment of steroid-resistant acute GVHD (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation; phase I clinical trial

View Full Paper

Ask AI

Bookmark

Authors

FHFatemeh Poorhoseini Hanzaii MSMasoud Soleimani AIAmirhossein IzadpanahShahid Beheshti University of Medical Sciences

Discussion

Member takes

Implication

Phase 1 clinical trial demonstrates favorable safety and a 73.6% overall response rate in steroid-resistant acute GVHD, suggesting a viable cell-free alternative to stem cell therapy.

Key Points

To evaluate the safety and therapeutic efficacy of placental mesenchymal stromal cell-derived extracellular vesicles (HP-MSCs-EV) in patients experiencing steroid-resistant acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Conducted a single-arm phase 1 clinical trial (IRCT20200413047063N6) from September 2024 to March 2025 in Tehran, Iran, enrolling 15 patients with steroid-refractory acute graft-versus-host disease.
Administered injections of human placenta-derived mesenchymal stromal cell extracellular vesicles (HP-MSCs-EV) and evaluated clinical response at days 7, 14, and 28 alongside safety outcomes including adverse events, infection, and relapse.
Achieved an overall response rate of 73.6% at day 28, consisting of complete response in 33.3% and partial response in 43.3% of patients, with skin and liver involvement predicting better clinical outcomes.
Significantly reduced systemic inflammatory markers (p ≤ 0.003) while maintaining stable baseline immune and hematologic parameters.
Reported no immediate injection-related adverse events, although infections occurred commonly across the 28-day follow-up period.

Cite This Study

Hanzaii et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2c5c562ede874ec7114 https://doi.org/10.1186/s13287-026-05259-z

View Full Paper

Ask AI

Bookmark

Implication

Phase 1 clinical trial demonstrates favorable safety and a 73.6% overall response rate in steroid-resistant acute GVHD, suggesting a viable cell-free alternative to stem cell therapy.

Evaluating the safety of placenta mesenchymal stromal cells-derived exosomes (HP-MSCs-EV) in the treatment of steroid-resistant acute GVHD (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation; phase I clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluating the safety of placenta mesenchymal stromal cells-derived exosomes (HP-MSCs-EV) in the treatment of steroid-resistant acute GVHD (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation; phase I clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider